These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 31649887)

  • 1. Circulating Tumor Biomarkers in Meningiomas Reveal a Signature of Equilibrium Between Tumor Growth and Immune Modulation.
    Erkan EP; Ströbel T; Dorfer C; Sonntagbauer M; Weinhäusel A; Saydam N; Saydam O
    Front Oncol; 2019; 9():1031. PubMed ID: 31649887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative protein profiling reveals minichromosome maintenance (MCM) proteins as novel potential tumor markers for meningiomas.
    Saydam O; Senol O; Schaaij-Visser TB; Pham TV; Piersma SR; Stemmer-Rachamimov AO; Wurdinger T; Peerdeman SM; Jimenez CR
    J Proteome Res; 2010 Jan; 9(1):485-94. PubMed ID: 19877719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunocytochemical analysis of glucose transporter protein-1 (GLUT-1) in typical, brain invasive, atypical and anaplastic meningioma.
    van de Nes JA; Griewank KG; Schmid KW; Grabellus F
    Neuropathology; 2015 Feb; 35(1):24-36. PubMed ID: 25168354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the results of recurrent intracranial meningiomas treated with re-radiosurgery.
    Kim M; Lee DH; Kim Rn HJ; Cho YH; Kim JH; Kwon DH
    Clin Neurol Neurosurg; 2017 Feb; 153():93-101. PubMed ID: 28081463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of merlin, NDRG2, ERBB2, and c-MYC in meningiomas: relationship with tumor grade and recurrence.
    Ongaratti BR; Silva CB; Trott G; Haag T; Leães CG; Ferreira NP; Oliveira MC; Pereira-Lima JF
    Braz J Med Biol Res; 2016; 49(4):e5125. PubMed ID: 27007654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Necrosis is a consistent factor to recurrence of meningiomas: should it be a stand-alone grading criterion for grade II meningioma?
    Góes P; Santos BFO; Suzuki FS; Salles D; Stávale JN; Cavalheiro S; de Paiva Neto MA
    J Neurooncol; 2018 Apr; 137(2):331-336. PubMed ID: 29270884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive overview of extracellular vesicle proteomics in meningioma: future strategy.
    Rana R; Sharma S; Ganguly NK
    Mol Biol Rep; 2021 Dec; 48(12):8061-8074. PubMed ID: 34687392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High throughput screening of meningioma biomarkers using a tissue microarray.
    Lusis EA; Chicoine MR; Perry A
    J Neurooncol; 2005 Jul; 73(3):219-23. PubMed ID: 15980972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Posttranscriptional deregulation of signaling pathways in meningioma subtypes by differential expression of miRNAs.
    Ludwig N; Kim YJ; Mueller SC; Backes C; Werner TV; Galata V; Sartorius E; Bohle RM; Keller A; Meese E
    Neuro Oncol; 2015 Sep; 17(9):1250-60. PubMed ID: 25681310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered expression of E-Cadherin-related transcription factors indicates partial epithelial-mesenchymal transition in aggressive meningiomas.
    Wallesch M; Pachow D; Blücher C; Firsching R; Warnke JP; Braunsdorf WEK; Kirches E; Mawrin C
    J Neurol Sci; 2017 Sep; 380():112-121. PubMed ID: 28870549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between laminin γ1 expression and meningioma grade, recurrence, and progression-free survival.
    Ke HL; Ke RH; Li B; Wang XH; Wang YN; Wang XQ
    Acta Neurochir (Wien); 2013 Jan; 155(1):165-71. PubMed ID: 23053286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracranial meningiomas, the VEGF-A pathway, and peritumoral brain oedema.
    Nassehi D
    Dan Med J; 2013 Apr; 60(4):B4626. PubMed ID: 23651727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy.
    Lamszus K; Lengler U; Schmidt NO; Stavrou D; Ergün S; Westphal M
    Neurosurgery; 2000 Apr; 46(4):938-47; discussion 947-8. PubMed ID: 10764269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic susceptibility contrast and dynamic contrast-enhanced MRI characteristics to distinguish microcystic meningiomas from traditional Grade I meningiomas and high-grade gliomas.
    Hussain NS; Moisi MD; Keogh B; McCullough BJ; Rostad S; Newell D; Gwinn R; Foltz G; Mayberg M; Aguedan B; Good V; Fouke SJ
    J Neurosurg; 2017 Apr; 126(4):1220-1226. PubMed ID: 27285539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CIP2A and PP2A in human leptomeninges, arachnoid granulations and meningiomas.
    Johnson MD; Reeder JE; O'Connell M; Woodford M; Walter K
    J Clin Neurosci; 2014 Dec; 21(12):2228-32. PubMed ID: 25012485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Na-K-2Cl cotransporter and aquaporin 1 in arachnoid granulations, meningiomas, and meningiomas invading dura.
    Johnson MD; O'Connell M
    Hum Pathol; 2013 Jun; 44(6):1118-24. PubMed ID: 23317544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.
    Dewan R; Pemov A; Dutra AS; Pak ED; Edwards NA; Ray-Chaudhury A; Hansen NF; Chandrasekharappa SC; Mullikin JC; Asthagiri AR; ; Heiss JD; Stewart DR; Germanwala AV
    BMC Cancer; 2017 Feb; 17(1):127. PubMed ID: 28193203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abundant immunohistochemical expression of dopamine D2 receptor and p53 protein in meningiomas: follow-up, relation to gender, age, tumor grade, and recurrence.
    Trott G; Pereira-Lima JF; Leães CG; Ferreira NP; Barbosa-Coutinho LM; Oliveira MC
    Braz J Med Biol Res; 2015 May; 48(5):415-9. PubMed ID: 25742638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thioredoxin-Interact ing-Pro t e in [TXNIP] and Transglutaminase 2 [TGM2] Expression in Meningiomas of Different Grades and the Role of Their Expression in Meningioma Recurrence and Prognosis.
    Harb OA; Elsayed WS; Ismail EI; Toam MM; Ammar MG
    Asian Pac J Cancer Prev; 2017 Aug; 18(8):2299-2308. PubMed ID: 28843270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II.
    Ruiz J; Martínez A; Hernández S; Zimman H; Ferrer M; Fernández C; Sáez M; López-Asenjo JA; Sanz-Ortega J
    Histol Histopathol; 2010 Mar; 25(3):341-9. PubMed ID: 20054806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.